CANbridge Pharma Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
67
- Stock Symbol
-
01228
- Share Price
-
$0.09
- (As of Wednesday Closing)
CANbridge Pharma General Information
Description
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.
Contact Information
Website
www.canbridgepharma.comCorporate Office
- Unit 18, 6th Floor, Building 21
- No.388 Xinping Street Suzhou Industrial Park
- Suzhou
- China
Corporate Office
- Unit 18, 6th Floor, Building 21
- No.388 Xinping Street Suzhou Industrial Park
- Suzhou
- China
CANbridge Pharma Stock Performance
As of 09-Jul-2025, CANbridge Pharma’s stock price is $0.09. Its current market cap is $37.3M with 425M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.09 | $0.07 | $0.01 - $0.11 | $37.3M | 425M | 7.05M | -$0.14 |
CANbridge Pharma Financials Summary
As of 31-Dec-2024, CANbridge Pharma has a trailing 12-month revenue of $11.9M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 22,876 | 22,876 | 37,347 | 66,472 |
| Revenue | 11,860 | 11,860 | 14,540 | 11,726 |
| EBITDA | (56,762) | (56,762) | (49,811) | (68,086) |
| Net Income | (61,685) | (61,685) | (53,547) | (71,790) |
| Total Assets | 16,002 | 16,002 | 55,774 | 101,756 |
| Total Debt | 18,599 | 18,599 | 20,022 | 22,507 |
CANbridge Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CANbridge Pharma Comparisons
Industry
Financing
Details
CANbridge Pharma Competitors (61)
One of CANbridge Pharma’s 61 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Innovent Biologics | Formerly PE-Backed | Shanghai, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
CANbridge Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CANbridge Pharma Patents
CANbridge Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3644062-B1 | Method for predicting esophagus cancer response to anti-erbb3 antibody treatment | Active | 22-Jun-2017 | ||
| EP-3644062-C0 | Method for predicting esophagus cancer response to anti-erbb3 antibody treatment | Active | 22-Jun-2017 | ||
| EP-3644062-A1 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Active | 22-Jun-2017 | ||
| EP-3644062-A4 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Active | 22-Jun-2017 | ||
| US-11834716-B2 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Active | 22-Jun-2017 | C12Q1/6886 |
CANbridge Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CANbridge Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CANbridge Pharma FAQs
-
When was CANbridge Pharma founded?
CANbridge Pharma was founded in 2012.
-
Where is CANbridge Pharma headquartered?
CANbridge Pharma is headquartered in Suzhou, China.
-
What is the size of CANbridge Pharma?
CANbridge Pharma has 67 total employees.
-
What industry is CANbridge Pharma in?
CANbridge Pharma’s primary industry is Pharmaceuticals.
-
Is CANbridge Pharma a private or public company?
CANbridge Pharma is a Public company.
-
What is CANbridge Pharma’s stock symbol?
The ticker symbol for CANbridge Pharma is 01228.
-
What is the current stock price of CANbridge Pharma?
As of 09-Jul-2025 the stock price of CANbridge Pharma is $0.09.
-
What is the current market cap of CANbridge Pharma?
The current market capitalization of CANbridge Pharma is $37.3M.
-
What is CANbridge Pharma’s current revenue?
The trailing twelve month revenue for CANbridge Pharma is $11.9M.
-
Who are CANbridge Pharma’s competitors?
Inhibrx, Innovent Biologics, BeOne Medicines, Dicerna Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 61 competitors of CANbridge Pharma.
-
What is CANbridge Pharma’s annual earnings per share (EPS)?
CANbridge Pharma’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
